18BGE047
18BGE047
18BGE047
ID:18BGE047
Asthma Definition
Irritants in the air: Different environment factors like pollen, dust, wood fire,
perfumes, chemical in the air, can also bring on an asthma episode. Although people
are not allergic to these items, they can bother inflamed, sensitive airways.
Hereditary: If your family has history of asthma or allergic diseases, you have higher
risk of developing asthma.
Triggers
Weather condition: Inhaling cold and dry air can cause the
airways to tighten and produce mucus, leading to asthma
symptoms like coughing, wheezing, and shortness of breath.
Infection: Viral infections, such as those caused by common cold viruses like
rhinoviruses, can inflame and irritate the airways, often leading to asthma
exacerbations. In young children, respiratory syncytial virus (RSV) can cause
severe respiratory symptoms and is a significant risk factor for developing
asthma later in life.
Tobacco smoke: If you or someone in your home smokes, you have a higher
risk of developing asthma.
Pathophysiology
IL-5
activates eosinophils which release different inflammatory mediators like
Major binding protein (MBP), Eosinophil peroxidase (EPO), Eosinophil cationic
protein (ECP), Tumor necrosis factor (TNF) which causes damage of the lung
epithelial.
A study of 4,000 adults initially aged 18–30 years, which was followed-up over 10 years
with serial spirometry measurements, found that
the decline in FEV1 was 8.5% in never smokers without asthma (n=2,393),
10.1% in non smokers with asthma (n=437) and 11.1% in smokers without
asthma(n=514).
The combination of asthma and smoking (n=101) had a synergistic effect on the decline in
lung function, and resulted in a 17.8% decline in FEV1 over 10 years.
In 2007, a telephone survey of 11,962 asthmatic adults in the United States revealed that
those who currently smoked reported more asthma attacks (OR, 1.2; 95% CI, 1.0 –1.4) and
more nocturnal asthma symptoms (OR, 2.0; 95% CI, 1.4 –2.7) during the past 30 days than
those who did not smoke.
Chances of Asthma in Children due to
Parental Smoking
Studies carried out in the United States in the 1970s were the first to
provide evidence of the effects of Passive smoking on lung function in
children exposed to ETS.
A wide-reaching prospective study in Germany, carried out on 7284
children between 9 and 11 years of age, found that children of parents
who smoked at home had lower peak expiratory flows and maximum
Expiratory flows at 75%, 50%, and 25%
In a systematic review of 39 international studies, demonstrate a direct
relation between Parental smoking and increased respiratory risk in
Children OR=1.7; (95% CI, 1.6-1.9) if the smoker was the mother and
OR=1.3; (95% CI, 1.2-1.4) if the smoker was the father
Asthma management strategies
Patient Education: Effective asthma management begins with educating patients about
their condition, including understanding their triggers and the proper use of
medications.
Monitoring Lung Function: Regular monitoring of asthma symptoms and lung function,
using tools like peak flow meters, allows for timely adjustments in treatment.
Anti IgE Antibody: Omalizumab is a humanized monoclonal antibody that targets the
high-affinity immunoglobulin E (IgE) receptor on mast cells, basophils, and dendritic
cells. This action reduces circulating IgE levels, preventing the release of mediators from
mast cells and basophils when exposed to allergens.
Anti Interleukin -4 antibody: IL-4 play a crucial role for asthma development. IL-4
activate and promoting isotype class switching of B cells to IgE synthesis and recruiting
mast cells. IL-4 binds to the interleukin-4 receptor α (IL-4Rα) present on the B cell &
plasma cell.
Dupilumab : An antibody that targets the IL-4 receptor alpha (IL-4Rα), inhibiting both
IL-4 and IL-13 signaling pathways. It is used to treat moderate to severe atopic asthma .
Emerging Treatment Approach